Expertise & Services

Expertise

Our expert team of scientists and technicians work in a state-of-the-art facility and balance work in research and development, which integrates seamlessly with the PC-TRiADD microarray facility, functional genomics and pathology service, as well as the clinical trials unit, to realize a comprehensive and focused translational research centre.

Services

  • Drug target identification and characterization
  • Computational drug discovery (virtual screening, combinatorial library construction, structure-activity modeling)
  • Computer-aided hit-to-lead optimization (ADME and Toxicity prediction, bioavailability and selectivity optimization)
  • Rapid and comprehensive evaluation of novel small molecules and biologics in preclinical model systems including:
    • Cytotoxicity assays
    • Clonogenic assays
    • Biomarker assays (established or novel)
    • Drug-target and off-target interaction assays
    • Drug-drug interactions
    • In Vitro and In Vivo tumour cell lines
    • GC and LC-MS assays for a variety of chemistries in biological matrices for GLP studies
  • Biomarker assay development
  • Single agent studies and combination studies
  • Pharmacodynamic and biomarker analysis of novel drugs in human clinical trials

The Living Tumor Laboratory

The Living Tumor Lab is a unique and valuable resource, which grows a wide variety of patient-derived cancer tissues, including both low and high-grade solid cancers.

This work enables researchers to readily study human cancer tissue in vivo and develop a variety of transplantable tumour tissue lines that can be used as models for studying cancer growth/progression/metastasis and drug sensitivity.

Visit the Living Tumor Laboratory website

News

Jul 26 2017

Dr. Zoubeidi awarded PCC-Movember Translation Acceleration Grant

July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.

Read more